ARCHIVES

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Plans Brain Tumor Study To Determine Risk Factors, Exposures

April 16, 1993

NCI renews Roswell Park’s core grant for five years.

September 26, 2003

Ethics Commission Acknowledges Weak Case For Mandatory Patient Compensation

April 23, 1982

FDA Commissioner Mark McClellan tells NCI audience that science is far from eliminating cancer as a threat.

February 6, 2004

Cediranib Demonstates Control In Alveolar Soft Part Sarcoma

May 31, 2013

Funding Opportunities: NCI Meeting Scheduled For Applicants Of RFA On Pediatric Consortium

February 27, 1998